No profile data available.
Mira Pharmaceuticals, Inc. (MIRA) is a healthcare company in the brain and nerve treatment drugs industry, based in Miami, United States.
It reported revenue of $0 for fiscal year 2024, and net income of -$7.85 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $31.33 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. , Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
Mira Pharmaceuticals reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$31.33 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include CervoMed Inc. (CRVO), Incannex Healthcare Inc. (IXHL), Quince Therapeutics, Inc. (QNCX), TAO Synergies Inc. (TAOX).